Compare ADX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADX | CDNA |
|---|---|---|
| Founded | N/A | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 1996 | 2007 |
| Metric | ADX | CDNA |
|---|---|---|
| Price | $25.25 | $87.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 238.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.45 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | N/A | $30.36 |
| Revenue Next Year | N/A | $6.23 |
| P/E Ratio | ★ N/A | $33.32 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $20.91 | $14.27 |
| 52 Week High | $26.56 | $73.43 |
| Indicator | ADX | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 40.10 | 80.69 |
| Support Level | $24.47 | $17.30 |
| Resistance Level | $25.50 | N/A |
| Average True Range (ATR) | 0.36 | 4.65 |
| MACD | -0.03 | 0.93 |
| Stochastic Oscillator | 7.11 | 86.08 |
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector-neutral approach. The fund has a diversified equity portfolio that consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.